Clinical and Translational Science (Apr 2024)

Differential expression and clinical significance of IGF2BP3 in peritoneal dialysate of patients with varying duration of peritoneal dialysis

  • Xiaoqi Shao,
  • Ling Yao,
  • Jiao Fu,
  • Mengmeng He,
  • Pei Zhang

DOI
https://doi.org/10.1111/cts.13774
Journal volume & issue
Vol. 17, no. 4
pp. n/a – n/a

Abstract

Read online

Abstract This study aims to investigate the differential expression of insulin‐like growth factor 2 mRNA‐binding protein 3 (IGF2BP3) in the peritoneal dialysate among patients with different durations of peritoneal dialysis and its association with the angiogenic marker vascular* endothelial growth factor (VEGF), the fibronectin (FN), and various clinical indicators. A cohort of 122 peritoneal dialysis patients was categorized into short‐term (≤1 year, n = 33), mid‐term (>1 and ≤5 years, n = 55), and long‐term (>5 years, n = 34) groups based on dialysis duration. We utilized enzyme‐linked immunosorbent assay (ELISA) and western blot assays to quantify the levels of IGF2BP3, VEGF, and FN in the dialysate. Our findings showed a progressive increase in IGF2BP3 levels with the duration of PD, with the long‐term group exhibiting significantly higher levels than both the short‐term and mid‐term groups (p < 0.001). A positive correlation between IGF2BP3 and VEGF (r = 0.386, p = 0.013), as well as between IGF2BP3 and FN (r = 0.340, p = 0.030), was observed. IGF2BP3 levels also correlated positively with serum creatinine, calcium, and phosphorus levels. In vitro analysis further confirmed that IGF2BP3 expression is enhanced in human peritoneal mesothelial cells under high‐glucose conditions (p < 0.05). The study highlights the potential of IGF2BP3 in PD effluent as a biomarker for monitoring PF progression, with its expression significantly correlated with the duration of PD (Pearson r = 0.897, p < 0.001). In conclusion, our results underscore a correlation between elevated IGF2BP3 levels and PD duration, suggesting the clinical significance of IGF2BP3 as a biomarker for PF progression.